ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

摘要:

Oral tazarotene, a novel receptor-selective retinoid, is effective in the treatment of psoriasis, according to studies presented at the 62nd Annual Meeting of the American Academy of Dermatology [Washington DC, US; February 2004]. Results from two phase III studies showed that treatment with tazarotene produced significant and durable improvements in symptoms and QOL, even in patients with very severe psoriasis. An open-label extension of these studies showed that long-term treatment with oral tazarotene was well tolerated and produced further improvements."A majority of patients achieve clinically meaningful improvement by week 12 of treatment with oral tazarotene; therefore, this may offer a new, once-daily systemic therapy option to people with moderate to severe psoriasis,"said Dr Alice Gottlieb from UMDNJ-Robert Wood Johnson Medical School in New Brunswick, US.

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

摘要:

The soluble tumour necrosis factor (TNF) receptor etanercept [Enbrel] produced high response rates in a phase III study involving more than 600 patients with psoriasis. Data presented at the 62nd Annual Meeting of the American Academy of Dermatology [Washington DC, US; February 2004] have shown that responses were maintained for approximately 3 months after treatment was discontinued, and that retreatment with etanercept after relapse produced similar reductions in PASI scores to those achieved with the original course of the drug. Furthermore, data from patients who did not achieve adequate responses during the initial 24-week treatment period showed that persisting with etanercept therapy can produce significant improvement in symptoms and QOL.

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2004

数据来源: ADIS